JP2015500861A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500861A5
JP2015500861A5 JP2014547997A JP2014547997A JP2015500861A5 JP 2015500861 A5 JP2015500861 A5 JP 2015500861A5 JP 2014547997 A JP2014547997 A JP 2014547997A JP 2014547997 A JP2014547997 A JP 2014547997A JP 2015500861 A5 JP2015500861 A5 JP 2015500861A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
compound according
independently selected
clause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500861A (ja
JP6062453B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076275 external-priority patent/WO2013092791A1/en
Publication of JP2015500861A publication Critical patent/JP2015500861A/ja
Publication of JP2015500861A5 publication Critical patent/JP2015500861A5/ja
Application granted granted Critical
Publication of JP6062453B2 publication Critical patent/JP6062453B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547997A 2011-12-22 2012-12-20 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物 Expired - Fee Related JP6062453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22
US61/578,979 2011-12-22
PCT/EP2012/076275 WO2013092791A1 (en) 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2015500861A JP2015500861A (ja) 2015-01-08
JP2015500861A5 true JP2015500861A5 (https=) 2016-02-04
JP6062453B2 JP6062453B2 (ja) 2017-01-18

Family

ID=47520068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547997A Expired - Fee Related JP6062453B2 (ja) 2011-12-22 2012-12-20 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物

Country Status (34)

Country Link
US (5) US8927543B2 (https=)
EP (3) EP2794604B1 (https=)
JP (1) JP6062453B2 (https=)
KR (1) KR102012268B1 (https=)
CN (1) CN103998448B (https=)
AR (1) AR089284A1 (https=)
AU (1) AU2012357067B2 (https=)
BR (1) BR112014015142B1 (https=)
CA (1) CA2859578C (https=)
CL (1) CL2014001664A1 (https=)
CO (1) CO7010835A2 (https=)
CR (1) CR20140305A (https=)
CY (2) CY1119434T1 (https=)
DK (2) DK2794604T3 (https=)
EA (1) EA023826B1 (https=)
ES (2) ES2643379T3 (https=)
HR (2) HRP20171404T1 (https=)
HU (1) HUE12812237T4 (https=)
IL (2) IL233212B (https=)
IN (1) IN2014MN01033A (https=)
LT (2) LT2794604T (https=)
MX (1) MX351681B (https=)
NI (1) NI201400060A (https=)
PE (1) PE20141685A1 (https=)
PH (1) PH12014501178B1 (https=)
PL (2) PL2794604T3 (https=)
PT (2) PT3378862T (https=)
SG (1) SG11201403169PA (https=)
SI (2) SI3378862T1 (https=)
TW (1) TWI567073B (https=)
UA (1) UA111767C2 (https=)
UY (1) UY34545A (https=)
WO (1) WO2013092791A1 (https=)
ZA (1) ZA201404607B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014095798A1 (en) * 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR102305710B1 (ko) * 2017-03-06 2021-09-30 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Gpr84 수용체 길항제 및 이의 용도
EP3403649A1 (en) * 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
RU2020119415A (ru) * 2017-11-15 2021-12-16 Галапагос Нв Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний
BR112022011237A2 (pt) 2019-12-19 2022-08-30 Bayer Ag Derivados de furoindazol
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2022112186A1 (en) 2020-11-24 2022-06-02 Galapagos Nv Compound for use in and methods of treatment of fibrotic diseases
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2022179940A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) * 2021-03-18 2022-09-27 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
EP4330260A1 (en) 2021-04-29 2024-03-06 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
WO2022268088A1 (zh) * 2021-06-21 2022-12-29 武汉人福创新药物研发中心有限公司 用于gpr84拮抗剂的三环化合物
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
CN120569392A (zh) * 2022-12-30 2025-08-29 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用
EP4698177A2 (en) * 2023-04-17 2026-02-25 The Board of Trustees of the Leland Stanford Junior University Method for detecting innate immune action in vivo using gpr84-pet
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
EP1017394B1 (en) * 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
CA2368460A1 (en) * 1999-03-31 2000-10-05 Alexander William Oxford Derivatives of pyrimido¬6,1-a|isoquinolin-4-one
EP1641766A2 (en) * 2003-07-08 2006-04-05 Smithkline Beecham Corporation Novel chemical compounds
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
EP1929310A2 (en) * 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
SG11201403268QA (en) 2011-12-22 2014-07-30 Connexios Life Sciences Pvt Ltd Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
RU2672468C1 (ru) 2011-12-22 2018-11-15 Конекшис Лайф Сайенсиз Пвт. Лтд. Производные аза-адамантанов и их применение
WO2014095798A1 (en) 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

Similar Documents

Publication Publication Date Title
JP2015500861A5 (https=)
JP2014523851A5 (https=)
JP2016525072A5 (https=)
JP2014530900A5 (https=)
JP2010525023A5 (https=)
JP2013528204A5 (https=)
JP2016528301A5 (https=)
JP2011502956A5 (https=)
JP2016532673A5 (https=)
CA2918284A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2016534063A5 (https=)
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
JP2016505637A5 (https=)
JP2013520473A5 (https=)
JP2016540811A5 (https=)
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
JOP20190052A1 (ar) 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
RU2006132195A (ru) Комбинация агонистов бета-2 адренорецептора, бензотиазол-2-онов и кортикостероидов, предназначенная для лечения респираторных заболеваний
JP2015527874A (ja) 肝細胞癌(hcc)患者の治療の有効な応答を決定するためのバイオマーカー
RU2015121037A (ru) Производные фенилэтилпиридина в качестве ингибиторов pde-4
JP2008531558A5 (https=)
US10570122B2 (en) Compounds with anti-tumoral activity
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
US20200181093A1 (en) Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines